332 related articles for article (PubMed ID: 24867254)
1. Folic acid: a biopharmaceutical evaluation.
Bellavinha KR; Silva-Barcellos NM; Souza JB; Leite JC; Souza Jd
Pharm Dev Technol; 2015; 20(6):730-7. PubMed ID: 24867254
[TBL] [Abstract][Full Text] [Related]
2. Influence of pH on the dissolution of folic acid supplements.
Younis IR; Stamatakis MK; Callery PS; Meyer-Stout PJ
Int J Pharm; 2009 Feb; 367(1-2):97-102. PubMed ID: 18929632
[TBL] [Abstract][Full Text] [Related]
3. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
[TBL] [Abstract][Full Text] [Related]
4. Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Folic Acid.
Hofsäss MA; Souza J; Silva-Barcellos NM; Bellavinha KR; Abrahamsson B; Cristofoletti R; Groot DW; Parr A; Langguth P; Polli JE; Shah VP; Tajiri T; Mehta MU; Dressman JB
J Pharm Sci; 2017 Dec; 106(12):3421-3430. PubMed ID: 28842299
[TBL] [Abstract][Full Text] [Related]
5. Agitation Rate and Time for Complete Dissolution in BCS Biowaivers Based on Investigation of a BCS Biowaiver for Dexketoprofen Tablets.
Garcia-Arieta A; Gordon J; Gwaza L; Mangas-Sanjuan V; Álvarez C; Torrado JJ
Mol Pharm; 2015 Sep; 12(9):3194-201. PubMed ID: 26237401
[TBL] [Abstract][Full Text] [Related]
6. Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hyclate drug products.
Strauch S; Jantratid E; Dressman JB
J Pharm Pharmacol; 2009 Mar; 61(3):331-7. PubMed ID: 19222905
[TBL] [Abstract][Full Text] [Related]
7. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
J Pharm Sci; 2014 Feb; 103(2):367-77. PubMed ID: 24301077
[TBL] [Abstract][Full Text] [Related]
8. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
9. Application of the BCS biowaiver approach to assessing bioequivalence of orally disintegrating tablets with immediate release formulations.
Ono A; Sugano K
Eur J Pharm Sci; 2014 Nov; 64():37-43. PubMed ID: 25151946
[TBL] [Abstract][Full Text] [Related]
10. Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine.
Gajendran J; Krämer J; Shah VP; Langguth P; Polli J; Mehta M; Groot DW; Cristofoletti R; Abrahamsson B; Dressman JB
J Pharm Sci; 2015 Oct; 104(10):3289-98. PubMed ID: 26149619
[TBL] [Abstract][Full Text] [Related]
11. Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications.
Suarez-Sharp S; Delvadia PR; Dorantes A; Duan J; Externbrink A; Gao Z; Ghosh T; Miksinski SP; Seo P
AAPS J; 2016 May; 18(3):578-88. PubMed ID: 26928450
[TBL] [Abstract][Full Text] [Related]
12. Biowaiver monographs for immediate-release solid oral dosage forms: ketoprofen.
Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
J Pharm Sci; 2012 Oct; 101(10):3593-603. PubMed ID: 22786667
[TBL] [Abstract][Full Text] [Related]
13. Justification of metformin hydrochloride biowaiver criteria based on bioequivalence study.
Homsek I; Parojcić J; Dacević M; Petrović L; Jovanović D
Arzneimittelforschung; 2010; 60(9):553-9. PubMed ID: 21117498
[TBL] [Abstract][Full Text] [Related]
14. Investigation of Biowaivers for Immediate Release Formulations Containing BCS III Drugs, Acyclovir, Atenolol, and Ciprofloxacin Hydrochloride, Using Dissolution Testing.
Reddy NH; Patnala S; Kanfer I
AAPS PharmSciTech; 2017 Feb; 18(2):424-431. PubMed ID: 27038483
[TBL] [Abstract][Full Text] [Related]
15. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products.
Okumu A; DiMaso M; Löbenberg R
Eur J Pharm Biopharm; 2009 May; 72(1):91-8. PubMed ID: 19056493
[TBL] [Abstract][Full Text] [Related]
16. Biowaiver monograph for immediate-release solid oral dosage forms: bisoprolol fumarate.
Charoo NA; Shamsher AA; Lian LY; Abrahamsson B; Cristofoletti R; Groot DW; Kopp S; Langguth P; Polli J; Shah VP; Dressman J
J Pharm Sci; 2014 Feb; 103(2):378-91. PubMed ID: 24382794
[TBL] [Abstract][Full Text] [Related]
17. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.
Tsume Y; Langguth P; Garcia-Arieta A; Amidon GL
Biopharm Drug Dispos; 2012 Oct; 33(7):366-77. PubMed ID: 22815122
[TBL] [Abstract][Full Text] [Related]
18. Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen.
Potthast H; Dressman JB; Junginger HE; Midha KK; Oeser H; Shah VP; Vogelpoel H; Barends DM
J Pharm Sci; 2005 Oct; 94(10):2121-31. PubMed ID: 16136567
[TBL] [Abstract][Full Text] [Related]
19. The Evaluation of Valsartan Biopharmaceutics Properties.
de Castro LML; de Souza J; Caldeira TG; de Carvalho Mapa B; Soares AFM; Pegorelli BG; Della Croce CC; Barcellos NMS
Curr Drug Res Rev; 2020; 12(1):52-62. PubMed ID: 31820707
[TBL] [Abstract][Full Text] [Related]
20. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
Heigoldt U; Sommer F; Daniels R; Wagner KG
Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
